Share Name Share Symbol Market Type Share ISIN Share Description
Lidco Group LSE:LID London Ordinary Share GB0030546849 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 7.875p 7.75p 8.00p 7.875p 7.875p 7.875p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 8.3 -2.2 -0.9 - 19.23

Lidco Share Discussion Threads

Showing 6251 to 6274 of 6275 messages
Chat Pages: 251  250  249  248  247  246  245  244  243  242  241  240  Older
DateSubjectAuthorDiscuss
24/5/2018
10:27
If anyone is hurting reeeeeeeeeal bad, I'm sure I would hear about it.
arf dysg
23/5/2018
18:54
Arf, I hope you know who, is hurting real bad.
willib2
23/5/2018
16:39
TrentEndBoy Now, now, no need for sarcasm. I have been precisely factual in comparing LidCo's share price to that of a year ago. If you find those facts unpleasant, I can't help that.
arf dysg
23/5/2018
14:04
Today as I key , in the USA there are HUP wise , 10+ centres in Purchasing process stage at this moment ( ie at least 11 ) Since LiDCO have signed 4 HUP deals since the HUP was first offered 10 months ago IMO LiDCO should get at least 5 new HUP deals signed by the end of this financial year. As LiDCO has signed a HUP deal with the '' Largest user of hemodynamic monitoring in USA'' Plus signed up a HUP deal with a large NHS Trust The chances of LiDCO signing up further HUP clients has been significantly enhanced.
buywell3
22/5/2018
22:17
Compared of course to doomedtex which is a multiple of price it was last year
trentendboy
21/5/2018
11:52
willib2 (5426) "Haha - you little tinker" Ah... somebody cares! P.S. The share price is still not higher than it was a year ago.
arf dysg
18/5/2018
14:12
The High Usage Program (HUP) was first launched July 2017 ( referred to in above post) It has been designed as a 'disruptive offering' in that it challenges all of LiDCO's competitors existing offerings by LiDCO offering something not only better technology wise ( so better patient outcomes) ... but also at a big saving costwise per patient ( so better for the Hospitals paying the bills) Since that date; in the USA there has been 4 significant HUP customers won: 1. Largest user of hemodynamic monitoring in USA 2. Major University of California healthcare centre 3. Level1 trauma centre in New York 4. 1000+ bed hospital Which is not bad , ie to get new LiDCO technology accepted , together with new long term HUP deals signed up and running ; all within 10 months. So in the USA 4 significant HUP customers won, but what is even better news is Today as I key , in the USA there are 10+ centres in Purchasing process stage at this moment This is something Mr Market has not yet factored in IMO
buywell3
18/5/2018
10:03
The HUP initiative as part of the new CEO's stategy for growth is looking like it is a winning formula for success. Chartwise LID looks like it could well have put in a second bottom at around 6p I would like to thank all those sellers at around that price 17 May 2018 AGM Statement LiDCO (AIM: LID), the hemodynamic monitoring company, will hold its Annual General Meeting today at 10am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ. At the meeting the Chairman, Peter Grant, will make the following statement: "This time last year, as planned, we invested significantly in the expansion of our commercial activities, strengthening both our sales efforts and promotional activities globally. Aligned to this, was the launch of our High Usage Programme (HUP) offering a unique unlimited license model focussing on attracting the larger more established users of hemodynamic monitoring to convert to LiDCO technology. HUP was launched in our key growth market, the US, but is now available in multiple territories. "To date we have signed multi-year HUP contracts with customers in both Europe and the US. In the latter, the Group now has four significant customers contracted, including the largest single site user of hemodynamic monitoring in the US. The two latest customers bring the total number of HUP monitors in the US to 66 units with 38 in Europe, including our largest customer in the UK, where we are market leader. We are confident that these new multi-year contracts will grow significantly beyond their initial orders. "As the business continues to win HUP contracts, we will transition towards multi-year license revenues, giving good visibility with recurring revenue and strong cash generation. This will greatly enhance the quality of the Company's earnings, although there will be a short-term impact on revenue recognition from new contracts as the income will typically be spread over the term of the contract as opposed to monitor sales being recognised up front. "Year to date, LiDCO sales are in line with the prior year, despite the comparative period including strong monitor sales. This reflects the positive impact HUP is having on our recurring revenues (being sales of smartcards, sensors, software licenses including HUP and service contracts). This is especially so in the US where recurring revenues are up 95% in local currency versus prior year. Whilst it is early in our financial year and the sales cycle for winning HUP contracts is lengthy, the Board is pleased with progress to date and trading remains in line with the Board's expectations.
buywell3
17/5/2018
18:53
Arf, "...and probably break even more investors' hearts." Haha - you little tinker
willib2
16/5/2018
18:43
Once upon a time doomedtex was higher than lid.Lid is now a multiple of doomedtex share price,What a shower over there and all too obvious. At least Arf sold out long ago - well done for listening Arf. Saved yourself a pretty penny by reading this board.Warms my heart to know we helped
trentendboy
16/5/2018
11:57
I was about to run around, frothing at the mouth and yelping "The share price is higher than it was a year ago!" ... but sadly, the share price is not higher than it was a year ago ... ...but I can run around yelping anyway.
arf dysg
16/5/2018
07:36
Ah "High Usage Programme (HUP) deferred revenues of £0.60m (2017: nil)" So thy have doubled that, nice but with market cap 16 million and loss making it does not tempt me to buy.
dave4545
16/5/2018
07:34
Recurring revenue up 95%, sounds good unless recurring revenues are tiny, easy to double your revenue if the existing revenue is small. Anybody know ?
dave4545
16/5/2018
07:22
Another update stating we have added 8 monitors in total to the HUP programme in the US between 2 big providers ! Very slow progress it appears, though we have apparently signed these amongst another 2 big players....you need the patience of all the saints in heaven put together to hold on to your LID investment :) I guess the LID will be firmly on the share price today....let's hope I am wrong !
multibagger
30/4/2018
11:50
willib, how's that?
arf dysg
27/4/2018
16:01
Arf tell this tool below that this happened over a decade a ago and it did not happen. gspanner27 Apr '18 - 10:17 - 9328 of 9329 Yes UK/NHS wide I’m afraid I agree; a mixture of departmental budgets and the dire management structures. If adopted by NICE that may force change.
willib2
12/4/2018
17:32
Tell you what, Buywell, if you give me 10p I'll take all your LID shares off your hands. No, that wasn't 10p per share.
arf dysg
10/4/2018
12:51
buywell3 (5415) "with the LID share price at 6.5p Lidco is now a sitting duck for the receiving of a low ball offer of 10p a share" That would be an extremely HIGH ball offer "Lidco traded at over 10p around a year ago" --- eight months ago actually, and very briefly.
arf dysg
10/4/2018
10:51
Some observations: with the LID share price at 6.5p Lidco is now a sitting duck for the receiving of a low ball offer of 10p a share Lidco traded at over 10p around a year ago, sales are now set to improve as the final results outlook indicates ''The Board is targeting a year of significant sales growth for LiDCO products in 2018/19 compared with the year just ended and believes that gross profit margins will return to historical levels due to higher recurring revenues. Operational expenses are expected to remain at a similar level to 2017/18. The Board believes that the Group has good prospects for growth and looks to the future with confidence.'' IMO a bid now of 10p would have to be referred to LID shareholders as it represents a premium of around 50% to the share price of LID today. Re the ''results'' today I add some comments after , of my own musings. 1. China ''As previously announced, during the year, the Group made no sales to its Chinese distributor due to the requirement to gain further regulatory approval in China for a key accessory and the new monitor. LiDCO is continuing to support its distributor in seeking these regulatory approvals, and whilst it is difficult to forecast exactly when this will be achieved, the Group anticipates this will be during 2018. The future prospects for LiDCO in the country remain strong and we do not believe that this temporary delay in our sales effort will reduce our ability to take share in this rapidly developing hemodynamic market in the medium term. Whilst the regulatory issue still needs resolving , and one would hope that what remains of 2018 should suffice, one would hope and expect that the current Chinese Distributor is building a back log of orders which can then be filled. A resumption of sales to China should add IMO £1M plus in the first year it is resumed , perhaps the use of the HUP model might also be rolled out in China soon after.'' 2. Lidco selling 3rd Party products in the UK ''Although notice has been given to terminate the distribution agreement for Argon Medical products at the end of September 2018, the Board aims to offset the effect of this by signing additional distribution agreements to take advantage of its sales reach in the UK.'' Argon was paying Lidco 20% for them to sell their products in the UK. This was a deal the new CEO was stuck with and has now ended. 20% is a very low percentage for a Distributor to agree to. 40% would be about the norm in the medical area from my research via other shares. I expect Lidco as it is in a MUCH stronger position to bargain from. Lidco is now the number one UK Hemodynamic monitor supplier to the NHS. When the previous deal was struck with Argon it was not. Thus Lidco should be able to strike a decent deal/s regarding the sale of 3rd party products into the NHS , using their position as a NHS approved supplier to do so. I would expect 30% plus as the new percentage for Lidco to obtain for such an undertaking/s. 3. Japan ''Excluding China, sales in ROW actually grew by 52% driven by strong growth in Japan and the Middle East. During the year, the Group announced the registration of its latest monitor platform and the appointment of Merit Medical Japan, a leading provider of critical care products, as its new exclusive distributor in Japan. Japan is the world's second largest market for advanced hemodynamic monitoring, it has a highly embedded market leader and is historically a conservative market to change. However, in the year, LiDCO experienced strong in-market growth of consumable sales and now, with the combined effects of launching our new monitor and partnering with Merit Medical, the Board believes that LiDCO is well positioned to gain greater market share in this important market. Following good growth in the Middle East in the previous year, the Group decided to invest in a locally based clinical training resource. Working with our master distributor, we are building a good foundation across multiple countries and have been able to register our products in other key countries such as Saudi Arabia. Sales to this country have been poor due to the previous deal signed with the previous distributor by the old CEO. Things should now change for the better, Japan is now a growth area for Lidco and the HUP model may well once again be used for more established larger users of Hemodynamic monitoring.'' 4. R.O.W The new CEO has a wealth of Hemodynamic monitoring sales experience and was a previous Sales Director for a Lidco competitor. He knows that the signing of a well worded deal with the 'right' distributor is key to sales growth for the company. I expect he will use his previous sales experience to Lidco's advantage,lucky for Lidco shareholders then. From the results today this outlook statement seems quite confident ... however will it now attract a bid from a larger predator that Lidco has already won work from in the USA ? wild card would be a Chinese company. ''Outlook The Board is targeting a year of significant sales growth for LiDCO products in 2018/19 compared with the year just ended and believes that gross profit margins will return to historical levels due to higher recurring revenues. Operational expenses are expected to remain at a similar level to 2017/18. The Board believes that the Group has good prospects for growth and looks to the future with confidence.''
buywell3
10/4/2018
07:48
Trading update disappointing...market will be brutal I think. Expect this to go down 3-4p on the cards unfortunately.
multibagger
10/4/2018
07:31
Oh dear me, what a terrible set of results, available cash down a whopping 33.3%, only 2 years cash left before a placing, HUP hasn't done much for the bottom line, so much for MSs magic touch.
gbenson1
09/4/2018
16:33
Happy Annual Increment, except that it's negative, oh dear.
arf dysg
29/3/2018
20:07
Hello All Idiots
maxk
29/3/2018
20:02
Here Am I?
arf dysg
Chat Pages: 251  250  249  248  247  246  245  244  243  242  241  240  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180524 10:16:19